LTX-315
Also known as: Oncopore, Ruxotemitide, VP-315
LTX-315 is an experimental intratumoral oncolytic peptide. Early uncontrolled studies show local tumor destruction and immune signals, but controlled clinical efficacy and marketing approval are not established.
Quick Facts
An intratumoral nine-residue peptide
LTX-315, also called oncopore or ruxotemitide, is developed by Lytix Biopharma for solid tumors such as melanoma. It is injected directly into tumor tissue and studied alone or with immunotherapy. This is an investigational cancer treatment, not a systemic peptide-wellness regimen.
The investigational oncolytic molecule consists of nine amino acids.
Tumor-cell disruption and immune priming
The peptide inserts into cell membranes and disrupts them, releasing tumor antigens and danger signals as tumor cells rupture. The proposed result is T-cell recruitment and potentially an abscopal response in uninjected lesions. Pairing it with checkpoint inhibitors aims to strengthen antitumor immunity. These are mechanistic goals rather than proof that uninjected tumors reliably respond.
Supporting references: cell membranes.
Sources: [1]
Early uncontrolled human findings
A Phase 1 dose-ranging trial in advanced solid tumors described tumor necrosis, T-cell infiltration, signs of systemic immune activity and at least 30% shrinkage of injected lesions in some patients. Standard objective responses to monotherapy were not observed. Later Phase 2 and combination findings were mainly company releases. Controlled efficacy trials have not established clinical benefit.
Distinct LTX-315 and VP-315 development paths
| Program | Developer/context | Milestone |
|---|---|---|
| LTX-315 | Lytix; high-risk resectable melanoma | Company reports FDA feedback supporting a path toward a registrational Phase 3 study; none completed |
| VP-315, licensed LTX-315 | Verrica; basal cell carcinoma | FDA accepted an IND in 2021 to begin Phase 2 research, not marketing approval |
Supporting references: accepted.
Sources: [2]
References and further reading
This reference draws on Superpower’s Peptide Library and the research linked below. Peptide Dossier’s editorial team adapted and integrated the material on .
- 10.1158/1078-0432.CCR-20-3435Tumor-cell disruption and immune primingCited in: Tumor-cell disruption and immune priming
- verrica.comDistinct LTX-315 and VP-315 development pathsCited in: Distinct LTX-315 and VP-315 development paths
Frequently Asked Questions About LTX-315
Related Peptides
Continue exploring LTX-315
Search all related references →Our library review is ongoing. Read how we evaluate evidence or report a correction.
Disclaimer: This article is for informational and educational purposes only. It is not intended as medical advice. The information presented is based on published research and should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting any peptide protocol. Some peptides discussed may not be approved for human use by the FDA or equivalent regulatory bodies.